Clinical Treatment of Mpox

• 2024

  Sign in to bookmark this resource.

  Sign in

---

Access Resources

• SummaryEN

About

This webpage describes the clinical treatment of mpox, focusing on tecovirimat (TPOXX) as a potential treatment option. It explains that while there is no FDA-approved treatment for mpox, tecovirimat is available under an expanded access program for patients with severe cases or specific conditions. The document outlines eligibility criteria, dosage instructions, and possible side effects of tecovirimat. It also highlights ongoing studies to assess its effectiveness and safety in treating mpox. Additionally, it provides information on other treatments like brincidofovir and Vaccinia Immune Globulin (VIGIV).

---

Tags

Hazard: Infectious Disease

Audiences: EMS Clinicians; Nurses; Physicians

Emergency Management Stage: Response

Keywords: Pain Management; Antiviral Agents; Clinical Trials as Topic; Monkeypox virus; Immunocompromised Host; Guidelines as Topic; Mpox (monkeypox)

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

About One Health 2024 · Centers for Disease Control and Prevention (CDC) Fact Sheet: United States Response to the Clade I Mpox Outbreak in Several African Countries 2024 · Centers for Disease Control and Prevention (CDC) Setting an agenda for a national pediatric trauma system: Operationalization of the Pediatric Trauma State Assessment Score 2023 · Pediatric Pandemic Network (PPN), University of California San Francisco, University of Louisville

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---